Related Experiment Video
Updated: Mar 14, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
The new EU regulation on in vitro diagnostics: potential issues at the interface of medicines and companion
Harald Enzmann1, Ralf Meyer1, Karl Broich1
1Bundesinstitut für Arzneimittel & Medizinprodukte, Bonn, Germany.
Abstract:
The new European regulation for in vitro diagnostics (IVD) divides the certification of IVD including companion diagnostics (CDx) by notified bodies (NB) from the market authorization of medicines. With the new regulation, CDx will require conformity assessment which is expected to include clinical evidence by NB. This is a significant change from the current situation: until now most IVD have been certified based on their manufacturers' assessment. For one medicine assessed by the EMA, certification of several different CDx by different NB is possible. As the benefit-risk balance of the medicine may depend on the performance (e.g., sensitivity and specificity) of its CDx, a close cooperation of EMA and NB will be necessary. The availability of detailed information on CDx used in the pivotal clinical trials for the medicine's authorization will become crucial for the assessment of alternative or competing CDx.
More Related Videos
09:30Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
07:43Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
Published on: July 14, 2023
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Drug Product Performance: In Vitro–In Vivo Correlation
In Vitro Drug Release Testing: Overview, Development and Validation
Clinically Relevant Drug Product Specifications: Methods of Establishment
Drug Regulation
Dosage Regimen: Individualization